Consolidated Statements of Cash Flows Statement (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net income (loss) including noncontrolling interests in operating subsidiaries	$ (23,853,000)	$ 49,567,000
Adjustments to reconcile net income including noncontrolling interests in operating subsidiaries to net cash provided by operating activities:
Depreciation and amortization	37,085,000	21,034,000
Non-cash stock compensation	20,812,000	17,375,000
Excess tax benefits from stock-based compensation	(358,000)	7,554,000
Change in valuation allowance	0	(10,237,000)
Other	(22,000)	490,000
Changes in assets and liabilities:
Accounts receivable	(6,969,000)	(13,720,000)
Prepaid expenses and other assets	(5,866,000)	(1,485,000)
Accounts payable and accrued expenses / costs	6,874,000	10,244,000
Royalties and contingent legal fees payable	(4,195,000)	(2,030,000)
Deferred income tax	(29,043,000)	6,546,000
Net cash provided by operating activities	(4,819,000)	70,230,000
Cash flows from investing activities:
Purchases of property and equipment	(579,000)	(200,000)
Purchase of available-for-sale investments	(232,809,000)	(305,007,000)
Maturities and sale of available-for-sale investments	155,669,000	169,016,000
Purchase of ADAPTIX, Inc., net of cash acquired	0	(150,000,000)
Patent acquisition costs	(10,416,000)	(64,960,000)
Net cash used in investing activities	(88,135,000)	(351,151,000)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	0	218,983,000
Distributions to noncontrolling interests in operating subsidiary	0	312,000
Payments of Dividends	(12,392,000)	0
Contributions from noncontrolling interests in operating subsidiary	1,920,000	3,840,000
Payments for Repurchase of Common Stock	(18,000)	0
Excess tax benefits from stock-based compensation	(358,000)	7,554,000
Proceeds from exercises of stock options	301,000	274,000
Net cash provided by financing activities	(10,547,000)	230,339,000
Decrease in cash and cash equivalents	(103,501,000)	(50,582,000)
Cash and cash equivalents, beginning	221,804,000	314,733,000
Cash and cash equivalents, ending	118,303,000	264,151,000
Patent acquisition costs included in accrued expenses	$ 9,750,000	$ 8,000,000